Downloads
Abstract
Molecular classification of breast cancer is target to category patient groups who need to treat by the appropriate adjuvant therapy and provide more exact prognostic information.
Purpose: Determining the proportion of molecular types and commenting on some association with clinicpathological characteristics of breast cancer.
Methods: 521 operated breast cancer patients were stained by immunohistochemistry with markes such as: ER, PR, HER2, and Ki67 for classifying into 5 molecular categories and follow up assessment.
Results: Type LUMBH- accounted for the highest proportion of 26.5%, followed by luminal A (22.5%). Typically, LUMA was the highest rate in good NPI (35.0%), whereas in poor NPI group, HER2 type was the highest rate (36.4%) (p<0.001). The LUMBH - group has the OS rate during the 5-year follow-up of 94.6% and LUMA is 93.5%; In contrast, the HER2 group showed the lowest OS ratio (72.6%) (p<0.05
Conclusion: Molecular classification of breast cancer according to St Gallen 2013 classification can provide the important information for treatment and prognosis.
References
Spitale. A, Mazzola P, Soldini D et al (2009). Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Annals of Oncology, 20, 628-635.
Perou. C.M, Sørlie T, Eisen M.B et al (2000). Molecular portraits of human breast tumours. Nature, 406(6797): 747-752.
Sorlie. T, Tibshirani R, Parker J et al (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA, 100(14), 8418-23.
Nielsen. T.O, Hsu F.D, Jensen K et al (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10, 5367-74.
Pang. T., Wang J, Bourne P (2008). Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?. Hum Pathol, 39(4), 506-13.
Untch M GB, Harbeck N, Jackisch C, Marschner N. Möbus V, et al. 13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus – Opinion of a German Team of Experts (Zurich 2013). Breast Care 2013;8:221-229
Bhargava. R, Esposito N.N and Dabbs D.J (2010). Immunohistology of the Breast. Diagnostic Immunohistochemistry: Theranostic and genomic applications, Saunders, USA, 763-819.
Engstrøm. M. J, Opdahl S, Hagen A.I (2013). Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat,140:463-73.
Haupt. B, Ro J.Y and Schwartz M.R (2010). Basal-like Breast Carcinoma A Phenotypically Distinct Entity. Arch Pathol Lab Med,134:130-133.
Adly. S, Hewedi .IH, Mokhtar N.M (2010). Clinicopathologic Significance of Molecular Classification of Breast Cancer: Relation to Nottingham Prognosis Index, Journal of the Egyptian Nat. Cancer Inst., Vol. 22, No. 4.
Zaha. D.C, Lazăr E, Lăzureanu C (2010). Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer. Romanian Journal of Morphology and Embryology, 51(1),85-89.
| Published | 11-01-2025 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 65 (2020) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.2020.65.16 | |
| Keywords | Ung thư vú, phân typ phân tử, hóa mô miễn dịch. Breast cancer, Imunohistochemistry, molecular classification. |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2020 Journal of Clinical Medicine Hue Central Hospital